Lawrence A. Leiter, MD, FRCP(C), FACP
Head, Division of Endocrinology and Metabolism
Director, Lipid Clinic
Associate Director, Clinical Nutrition and Risk Factor Modification Centre
St. Michael’s Hospital
Professor of Medicine and Nutritional Sciences
University of Toronto
Toronto, Ontario
Canada
Can you summarize the key features of the LEADER trial, including the primary MACE end points and the patient populations studied?
What metabolic and hemodynamic parameters were affected most significantly in LEADER and what new information did we learn about the safety profile of liraglutide?
In your view, what impact should, and will, the LEADER trial have on clinical management of patients with T2D, especially those at risk for cardiovascular disease?
Given the positive results of LEADER, can you speculate on the likely mechanisms that explain the CV risk reduction that was observed?
What are the significant differences in time points and types of vascular benefits seen in LEADER using a GLP-1 RA vs the EMPA-REG trial which evaluated an SGLT2 inhibitor?
What did we learn from the reduction in microvascular end points — including those reflecting renal function — reported in the LEADER trial?
What did we learn from the LEADER trial about regimen adherence with once-daily liraglutide?
What did we learn from the LEADER trial about regimen adherence with once-daily liraglutide?
What is the principal take-away from the LEADER trial about the role of liraglutide in patients with T2D and CV risk factors?